Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,381.40 | 9.10 | -0.10% |
| CAC 40 | 8,650.56 | 24.38 | -0.28% |
| DAX 40 | 26,299.74 | 31.33 | -0.12% |
| Dow JONES (US) | 53,839.99 | 69.72 | 0.13% |
| FTSE 100 | 10,772.67 | 60.48 | -0.56% |
| HKSE | 25,396.51 | 43.66 | -0.17% |
| NASDAQ | 26,803.03 | 214.54 | 0.81% |
| Nikkei 225 | 68,308.59 | 784.53 | 1.16% |
| NZX 50 Index | 13,860.96 | 35.66 | 0.26% |
| S&P 500 | 7,798.99 | 50.49 | 0.65% |
| S&P/ASX 200 | 9,188.50 | 4.40 | -0.05% |
| SSE Composite Index | 3,926.96 | 19.71 | -0.50% |